Treatment with recombinant tissue plasminogen activator (rt-PA) has been applied in acute cardioembolic stroke to reopen the occluded vessel and improve the patient’s neurologic deficit. However, the effect of this therapy on intracardiac thrombus has not been documented previously A forty-five-year-old man with dilated cardiomyopathy developed acute cardioem-bolic stroke with disturbance of consciousness, right hemianopia, right hemiplegia, and global aphasia. Cerebral angiography demonstrated occlusion of the left middle cerebral artery trunk. Intravenous administration of 30 megaunits (MU) of recombinant tissue plasminogen activator was commenced two hours after the ictus and completed within sixty minutes. Cerebral angiography was repea...
Recombinant tissue plasminogen activator (rTPA) is one of the main portions of acute ischemic stroke...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...
Many reports focus on the probability of intracranial hemorrhage as a complication after recombinant...
Background and Purpose—Mechanisms of early neurologic deterioration after treatment with intravenous...
Early recurrent cardioembolic stroke on the previously unaffected side has very rarely been reported...
Pulmonary embolism can be a catastrophic event that can result in early death or serious hemodynamic...
textabstractAn intravenous infusion of 40 mg of recombinant tissue-type plasminogen activator (rt-PA...
Intravenous recombinant human tissue plasminogen activator (rtPA, formulated as alteplase) is the pr...
The primary aim of thrombolysis in acute ischemic stroke is recanalization of an occluded intracrani...
INTRODUCTION: Acute ischemic stroke (AIS) represents a major cause of death and disability all over ...
cation occlusion with involvement of A1 and M1 segments) is associated with poor outcome. In most ca...
When conventional treatment of patients with early clinical reinfarction after thrombolytic therapy ...
A number of landmark trials have proven the efficacy of thrombolysis by intravenous recombinant tiss...
Over the past 50 years, thrombolytic agents have been devised with the aim of recanalizing occluded ...
Recombinant tissue plasminogen activator (rTPA) is one of the main portions of acute ischemic stroke...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...
Many reports focus on the probability of intracranial hemorrhage as a complication after recombinant...
Background and Purpose—Mechanisms of early neurologic deterioration after treatment with intravenous...
Early recurrent cardioembolic stroke on the previously unaffected side has very rarely been reported...
Pulmonary embolism can be a catastrophic event that can result in early death or serious hemodynamic...
textabstractAn intravenous infusion of 40 mg of recombinant tissue-type plasminogen activator (rt-PA...
Intravenous recombinant human tissue plasminogen activator (rtPA, formulated as alteplase) is the pr...
The primary aim of thrombolysis in acute ischemic stroke is recanalization of an occluded intracrani...
INTRODUCTION: Acute ischemic stroke (AIS) represents a major cause of death and disability all over ...
cation occlusion with involvement of A1 and M1 segments) is associated with poor outcome. In most ca...
When conventional treatment of patients with early clinical reinfarction after thrombolytic therapy ...
A number of landmark trials have proven the efficacy of thrombolysis by intravenous recombinant tiss...
Over the past 50 years, thrombolytic agents have been devised with the aim of recanalizing occluded ...
Recombinant tissue plasminogen activator (rTPA) is one of the main portions of acute ischemic stroke...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...